Clinical and Experimental Ophthalmology

Papers
(The H4-Index of Clinical and Experimental Ophthalmology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Past Lecturers and Briefs For the Named Lectures: RANZCO Annual Scientific Congress196
Continuing Professional Development91
Issue Information80
Issue Information68
Proposal of a Simpler Eye‐Level Risk Model Incorporating Reticular Pseudodrusen for the Clinical Prediction of Late Age‐Related Macular Degeneration54
Role of chloramphenicol eye drops for endophthalmitis prophylaxis following cataract surgery: Outcomes of institutional cessation50
The association between keratoconus and allergic eye diseases: A systematic review and meta‐analysis50
Vaccination with circulating exosomes in autoimmune uveitis prevents recurrent intraocular inflammation48
Fluid misdirection syndrome associated with endothelial keratoplasty: A multicenter case series43
Improved methods for isolating the mouse retinal vasculature40
Circular RNA expression profile and functional analysis of circUvrag in light‐induced photoreceptor degeneration38
Recent advances in the use of optical coherence tomography in neuro‐ophthalmology: A review36
Genetics in neovascular age‐related macular degeneration susceptibility and treatment response to anti‐VEGF intravitreal injection: A case series study36
Telemedicine and delivery of ophthalmic care in rural and remote communities: Drawing from Australian experience35
Mimickers of hydroxychloroquine retinal toxicity27
Microbiological diagnosis of endophthalmitis using nanopore targeted sequencing27
Continuing Professional Development27
Continuing Professional Development26
Issue Information23
Durability of anti‐vascular endothelial growth factor agents in neovascular age‐related macular degeneration20
Issue Information20
Continuing Professional Development20
20
Bevacizumab biosimilar (bevacizumab‐awwb) is safe in the treatment of retinopathy of prematurity20
Sunday 27 February Speakers20
0.031574010848999